-
Mashup Score: 16I'm supporting the American Diabetes Association! - 14 hour(s) ago
The American Diabetes Association mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes. Let’s join together to fight diabetes!
Source: stepout-diabetes.donordrive.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1Research Opportunities - 17 hour(s) ago
The latest opportunities for advancing endocrinology research
Source: www.endocrine.orgCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 36
SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These effects were consistent across a wide range of subgroups within these populations. This supports the eligibility of a large population with cardiorenal-metabolic diseases for treatment with SGLT2 inhibitors.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 113Sleep and cardiometabolic health—not so strange bedfellows - 20 hour(s) ago
“Sleep dwell upon thine eyes, peace in thy breast.” Romeo and Juliet (Act 2, Scene 2), William Shakespeare (1597)
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 5
Melatonin, a hormone primarily produced by the brain’s pineal gland, is typically secreted during darkness, aligning with the time when most people sleep. Melatonin plays a crucial part in signalling the onset of the biological night. It achieves this through multiple mechanisms, including inhibiting wake-promoting orexin neurons located in the hypothalamus, which serves as a central hub for regulating the sleep–wake cycle.1 The fact that melatonin can help to regulate sleep timing might also explain its popularity, particularly in countries where it is available over the counter.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 36Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies - 22 hour(s) ago
With up to 23 years of follow-up of three large prospective cohorts of middle-aged and older men and women, self-reported melatonin supplement use was not associated with risk of type 2 diabetes or cardiovascular disease. Further research is warranted to assess if melatonin supplement use could mitigate the potential risks of type 2 diabetes and cardiovascular disease associated with rotating night shift work.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 100Sleep: a neglected public health issue - 23 hour(s) ago
Controlled by circadian rhythms and sleep–wake homeostasis, sleep is a state of reduced mental and physical activity—a time for body and mind to recharge in preparation for the next day. Although adults aged 18 years and older are recommended to get 7–9 h of sleep per day (and children up to 12 h), the 24/7 economy, modern lifestyles, job stresses, and living environments adversely affect the timing, duration, and quality of sleep for many people.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 27
Nature Reviews Endocrinology – This Review discusses the role of AMPK in cancer cachexia and metabolic dysfunction, including discussion of how targeting AMPK might be an option to preserve muscle…
Source: www.nature.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 1SGLT2 inhibitors in clinical practice - 1 day(s) ago
On Sept 15, 2015, in Stockholm, the attendees at the Congress of the European Association for the Study of Diabetes were stunned by the presentation of the first randomised investigation of a sodium–glucose co-transporter-2 (SGLT2) inhibitor, empagliflozin, in the EMPA-REG OUTCOME trial1 in patients with type 2 diabetes and atherosclerotic cardiovascular disease. The unexpected results (ie, an early-onset reduction in morbidity and mortality) caused the audience to stand up and applaud the first evidence that a drug, developed to lower glucose concentration, was associated with cardiovascular superiority due to a reduction of heart failure.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 36
SGLT2 inhibitors reduced heart failure events and cardiovascular death in patients with heart failure, type 2 diabetes, chronic kidney disease, and atherosclerotic cardiovascular disease. These effects were consistent across a wide range of subgroups within these populations. This supports the eligibility of a large population with cardiorenal-metabolic diseases for treatment with SGLT2 inhibitors.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
👟Lace up your sneakers and join us today for #NationalWalkingDay! Walking is a simple yet effective way to improve blood glucose management, boost heart health, and more. Be sure to check if there's a Step Out® near you or join our virtual walk at https://t.co/PQHMb03fSj. https://t.co/N7NjORzn1c